The clinically active PARP inhibitor AG014699 ameliorates cardiotoxicity but does not enhance the efficacy of doxorubicin, despite improving tumor perfusion and radiation response in mice.
about
Mitochondrial dysfunction induces Sarm1-dependent cell death in sensory neuronsPharmacokinetics and efficacy of PEGylated liposomal doxorubicin in an intracranial model of breast cancer.Vasoactivity of rucaparib, a PARP-1 inhibitor, is a complex process that involves myosin light chain kinase, P2 receptors, and PARP itself.Role of PARP inhibitors in cancer biology and therapyTherapeutic applications of PARP inhibitors: anticancer therapy and beyondInhibiting the DNA damage response as a therapeutic manoeuvre in cancer.Human resistin in chemotherapy-induced heart failure in humanized male mice and in women treated for breast cancer.The La antigen is over-expressed in lung cancer and is a selective dead cancer cell target for radioimmunotherapy using the La-specific antibody APOMAB®.Altered RECQL5 expression in urothelial bladder carcinoma increases cellular proliferation and makes RECQL5 helicase activity a novel target for chemotherapy.PARP inhibitor reduces proliferation and increases apoptosis in breast cancer cells.The potential of PARP inhibitors in neuro-oncology.Nanoformulation of Olaparib Amplifies PARP Inhibition and Sensitizes PTEN/TP53-Deficient Prostate Cancer to Radiation.Pathways of cardiac toxicity: comparison between chemotherapeutic drugs doxorubicin and mitoxantrone.Tumor Cell Recovery from Senescence Induced by Radiation with PARP Inhibition.Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases.Rucaparib: First Global Approval.PARP inhibition sensitizes to low dose-rate radiation TMPRSS2-ERG fusion gene-expressing and PTEN-deficient prostate cancer cells.Optimize radiochemotherapy in pancreatic cancer: PARP inhibitors a new therapeutic opportunityAn assay to measure poly(ADP ribose) glycohydrolase (PARG) activity in cellsRadiosensitization with an inhibitor of poly(ADP-ribose) glycohydrolase: A comparison with the PARP1/2/3 inhibitor olaparib.Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research-practice gaps, challenges, and insights.Poly(ADP-ribose) polymerase 1 deficiency increases nitric oxide production and attenuates aortic atherogenesis through downregulation of arginase II.Characterization and drug sensitivity of a novel human ovarian clear cell carcinoma cell line genomically and phenotypically similar to the original tumor
P2860
Q33865342-617DF43E-F90F-4033-B612-58CB72612EDBQ34708283-AA1C40CA-1525-4967-A924-8F61DCDECFCCQ35092269-0AAF6808-BD1C-4564-B9BC-3879C820763EQ36171193-7C5CDD24-740F-4B87-AA8E-A9D31AF75116Q36853236-F5303A84-34F2-446F-8011-BB2BBF27C899Q37122690-6DF555F7-EF74-4A16-99DB-77FE19042694Q37240194-0C98FC0F-F739-47B0-83D8-27AB8B5A267FQ37438751-8A7DF18A-9308-44C8-A8D2-20A04F0D2F98Q37689080-80BDC461-D406-4C36-82DF-F0E8B5D39CBBQ37725419-E8B004B1-4A6E-415D-9435-3DB81FC2C77AQ38233068-3074CE07-2057-447B-833D-3647031CFD18Q38788554-720C9A12-8571-42AF-BB0E-68DE1DB20831Q38876257-3694E8FC-8D37-4560-B4A7-7E4871E60989Q38944795-576C40D2-2681-40EB-A22C-7119DC497383Q38954348-904441F2-ED28-45E1-9D38-C868763DD1A7Q39155735-8F76F90D-F5DB-4772-B0D7-399552205F72Q39169663-1B0F765E-EACE-47CF-A0FA-56C68C31B9D9Q39245474-2B7A8DA5-24F5-4196-9DB1-DDE95B9F42D8Q41315657-A3C12441-1935-4396-8558-F666B9E7AD16Q47360676-9C237F0C-01C6-4D46-85AB-B09775AEFD54Q49315568-CEF0BD5A-AB9B-4074-A9EB-B1B3E835D11BQ51376719-D58B71AC-11D4-4AD2-ADFE-3A429989D35EQ58779796-344AB3BB-7A7C-4383-8360-3FEE1ED8C6A5
P2860
The clinically active PARP inhibitor AG014699 ameliorates cardiotoxicity but does not enhance the efficacy of doxorubicin, despite improving tumor perfusion and radiation response in mice.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
The clinically active PARP inh ...... nd radiation response in mice.
@ast
The clinically active PARP inh ...... nd radiation response in mice.
@en
type
label
The clinically active PARP inh ...... nd radiation response in mice.
@ast
The clinically active PARP inh ...... nd radiation response in mice.
@en
prefLabel
The clinically active PARP inh ...... nd radiation response in mice.
@ast
The clinically active PARP inh ...... nd radiation response in mice.
@en
P2093
P2860
P1476
The clinically active PARP inh ...... nd radiation response in mice.
@en
P2093
Brian A Telfer
Huw D Thomas
Ivanda Pavlovska
Kaye J Williams
Marzieh Kamjoo
Muhammed Babur
Nicola J Curtin
Suzanne Kyle
P2860
P304
P356
10.1158/1535-7163.MCT-11-0356
P577
2011-09-16T00:00:00Z